These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 29862440)

  • 21. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Sinshaw W; Kebede A; Bitew A; Tesfaye E; Tadesse M; Mehamed Z; Yenew B; Amare M; Dagne B; Diriba G; Alemu A; Getahun M; Fikadu D; Desta K; Tola HH
    BMC Infect Dis; 2019 Jul; 19(1):641. PubMed ID: 31324227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study.
    Huang H; Zhang Y; Li S; Wang J; Chen J; Pan Z; Gan H
    Microb Drug Resist; 2018 Jun; 24(5):675-679. PubMed ID: 29053085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
    van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
    PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Xpert® MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia.
    Mavenyengwa RT; Shaduka E; Maposa I
    Infect Dis Poverty; 2017 Jan; 6(1):13. PubMed ID: 28086955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa.
    Schnippel K; Meyer-Rath G; Long L; Stevens WS; Sanne I; Rosen S
    S Afr Med J; 2013 Jan; 103(2):101-6. PubMed ID: 23374320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Catching the missing million: experiences in enhancing TB & DR-TB detection by providing upfront Xpert MTB/RIF testing for people living with HIV in India.
    Raizada N; Sachdeva KS; Sreenivas A; Kulsange S; Gupta RS; Thakur R; Dewan P; Boehme C; Paramsivan CN
    PLoS One; 2015; 10(2):e0116721. PubMed ID: 25658091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype®MTBDRplus and Xpert®MTB/RIF in the diagnosis of tuberculosis and resistant tuberculosis: cost analysis in a tertiary referral hospital.
    Soares VM; Almeida IN; Vater MC; Alves S; Figueredo LJA; Scherer L; Kritski AL; Carvalho WDS; Miranda SS
    Rev Soc Bras Med Trop; 2020; 53():e20190175. PubMed ID: 32049199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting.
    Rice JP; Seifert M; Moser KS; Rodwell TC
    PLoS One; 2017; 12(10):e0186139. PubMed ID: 29016684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design.
    Naidoo P; Dunbar R; Lombard C; du Toit E; Caldwell J; Detjen A; Squire SB; Enarson DA; Beyers N
    PLoS One; 2016; 11(3):e0150487. PubMed ID: 26930400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of HIV-positive patients with non-tuberculous mycobacteria positive culture who received anti-tuberculous treatment in Botswana: Implications of using diagnostic algorithms without non-tuberculous mycobacteria.
    Agizew T; Boyd R; Mathebula U; Mathoma A; Basotli J; Serumola C; Pals S; Finlay A; Lekone P; Rankgoane-Pono G; Tlhakanelo T; Chihota V; Auld AF
    PLoS One; 2020; 15(6):e0234646. PubMed ID: 32530972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey.
    Dorman SE; Chihota VN; Lewis JJ; Shah M; Clark D; Grant AD; Churchyard GJ; Fielding KL
    PLoS One; 2012; 7(8):e43307. PubMed ID: 22905254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mixed impact of Xpert(®) MTB/RIF on tuberculosis diagnosis in Cambodia.
    Auld SC; Moore BK; Kyle RP; Eng B; Nong K; Pevzner ES; Eam KK; Eang MT; Killam WP
    Public Health Action; 2016 Jun; 6(2):129-35. PubMed ID: 27358807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia.
    Biadglegne F; Mulu A; Rodloff AC; Sack U
    Tuberculosis (Edinb); 2014 Sep; 94(5):502-5. PubMed ID: 24931451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis.
    Pantoja A; Fitzpatrick C; Vassall A; Weyer K; Floyd K
    Eur Respir J; 2013 Sep; 42(3):708-20. PubMed ID: 23258774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Has universal screening with Xpert® MTB/RIF increased the proportion of multidrug-resistant tuberculosis cases diagnosed in a routine operational setting?
    Naidoo P; Dunbar R; Caldwell J; Lombard C; Beyers N
    PLoS One; 2017; 12(2):e0172143. PubMed ID: 28199375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Light-emitting diode fluorescent microscopy and Xpert MTB/RIF® assay for diagnosis of pulmonary tuberculosis among patients attending Ambo hospital, west-central Ethiopia.
    Gelalcha AG; Kebede A; Mamo H
    BMC Infect Dis; 2017 Sep; 17(1):613. PubMed ID: 28893193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of algorithms for tuberculosis active case finding in underserved high-prevalence settings in Cambodia: a cross-sectional study.
    Choun K; Decroo T; Mao TE; Lorent N; Gerstel L; Creswell J; Codlin AJ; Lynen L; Thai S
    Glob Health Action; 2019; 12(1):1646024. PubMed ID: 31500551
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB.
    Tsuyuguchi K; Nagai H; Ogawa K; Matsumoto T; Morimoto K; Takaki A; Mitarai S
    J Infect Chemother; 2017 Feb; 23(2):101-106. PubMed ID: 27919693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.